---
layout: default
title: Vemurafenib
parent: AI Predictions (L5)
nav_order: 638
evidence_level: L5
indication_count: 10
---

# Vemurafenib
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Vemurafenib: From BRAF V600E-Mutant Melanoma to HIV Infection

## One-Sentence Summary

> Vemurafenib is a BRAF V600E-selective kinase inhibitor, contextually used to treat BRAF V600E-mutant melanoma (the drug's formal original-indication text is not present in this Evidence Pack, but is consistently implied by the accompanying literature and rationale entries).
> The TxGNN model's top-ranked prediction is **HIV infectious disease**, but this signal is currently supported by **0 clinical trials** and **0 publications**, and the pack itself flags "no known mechanistic association" between BRAF inhibition and HIV pathways.
> This is a pure knowledge-graph similarity prediction with no biological or clinical corroboration to date.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this Evidence Pack (no `taiwan_regulatory.licenses` entries); contextually consistent with BRAF V600E-mutant melanoma based on accompanying literature |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 97.65% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack (flagged as a High-severity data gap). Based on contextual information within the pack — including literature titles referencing "vemurafenib for BRAF-mutated melanoma" and repeated mentions of "BRAF V600E-specific inhibition" — vemurafenib appears to function as a selective inhibitor of the mutated BRAF kinase, a key node in the MAPK signaling pathway that drives proliferation in BRAF V600E-positive tumors.

For this top-ranked prediction, the relationship between the original indication (oncogenic BRAF-driven signaling) and the predicted new indication (HIV infectious disease) has **no established mechanistic basis**. The Evidence Pack's own rationale for this candidate states explicitly: *"BRAF V600E inhibition has no known association with HIV viral replication or host immune pathways; this is purely a knowledge-graph similarity prediction."*

In other words, this candidate was surfaced by the TxGNN model on the basis of network-embedding similarity rather than any pharmacological, virological, or immunological rationale. It should be treated as a hypothesis-generating signal only, not as evidence of biological plausibility.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Cytotoxicity

Contextual evidence in this Evidence Pack (literature entries repeatedly describing vemurafenib as a melanoma-directed BRAF V600E inhibitor) supports classifying this as an antineoplastic/targeted agent, though no structured DrugBank category or toxicity data were provided.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (BRAF V600E kinase inhibitor) — inferred from contextual literature, not from structured category data |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |

---

## Safety Considerations

Please refer to the SmPC for safety information.

Note: this drug also carries a **Blocking**-severity data gap in the underlying Evidence Pack — official label warnings/contraindications have not yet been retrieved, which prevents any formal S1 safety pre-assessment.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (HIV infectious disease) has no clinical trials, no supporting literature, and no plausible mechanistic link per the pack's own rationale — it is an L5, model-only signal that does not meet the evidentiary bar to advance.

**To proceed, the following is needed:**
- Official product label / SmPC data (warnings, contraindications, DDI) to close the Blocking-severity safety data gap
- Confirmed mechanism of action (MOA) sourced from DrugBank or equivalent regulatory documentation
- Independent biological rationale (in vitro or in vivo) connecting BRAF/MAPK inhibition to HIV pathophysiology before any experimental investment
- Formal confirmation of the original approved indication and regulatory status, since no EU marketing authorization is currently on file

**Additional observation (secondary signal, not part of the primary S0 candidate):**
Among the other nine ranked predictions in this pack, **female breast carcinoma** (rank 8) stands out with a materially higher evidence tier (L3, "Research Question" stage) — it has one early-phase (withdrawn) trial and 19 literature citations, including case reports of BRAF V600E-mutant triple-negative breast cancer as well as a conflicting case report of vemurafenib-associated breast cancer progression. If further repurposing exploration is warranted for this molecule, that candidate — not the HIV signal — would be the more defensible starting point, though the mixed direction of effect (efficacy vs. progression) still requires subgroup clarification before advancing.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

